Aptus Capital Advisors’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Aptus Capital Advisors’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.7K	Hold	400	–	–	﹤0.01%	1502
2026 Q1	$17.5K	Hold	400	–	–	﹤0.01%	1433
2025 Q4	$18.2K	Hold	400	–	–	﹤0.01%	1430
2025 Q3	$15.5K	Buy	400 +300	+300%	+$10.9K	﹤0.01%	1387
2025 Q2	$3.37K	Hold	100	–	–	﹤0.01%	1448
2025 Q1	$3.18K	Hold	100	–	–	﹤0.01%	1359
2024 Q4	$3.89K	Hold	100	–	–	﹤0.01%	1347
2024 Q3	$4.5K	Hold	100	–	–	﹤0.01%	1148
2024 Q2	$4.18K	Buy	+100	New	+$4.18K	﹤0.01%	1085

Other funds holding GNOM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

OAM

Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

CFD

Creative Financial Designs Kokomo, Indiana $2.1B AUM 23.1% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

FIA

Foundations Investment Advisors Phoenix, Arizona $9.72B AUM 29.41% 1-Year Est. Return

Aptus Capital Advisors's GNOM Position: Q2 2026 in Review

Aptus Capital Advisors held its Global X Genomics & Biotechnology ETF (GNOM) position steady in Q2 2026 at 400 shares worth $22.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1502.

Aptus Capital Advisors first reported a position in GNOM in Q2 2024 and has held it in 9 quarters since. 48 funds tracked by Wall St. Rank hold GNOM as of Q2 2026.

Aptus Capital Advisors held 400 shares of Global X Genomics & Biotechnology ETF worth $22.7K as of Q2 2026.
Aptus Capital Advisors left its Global X Genomics & Biotechnology ETF share count unchanged in Q2 2026.
Global X Genomics & Biotechnology ETF made up ﹤0.01% of Aptus Capital Advisors's portfolio in Q2 2026, its #1502 holding.
Aptus Capital Advisors first reported a position in Global X Genomics & Biotechnology ETF in Q2 2024 and has held it in 9 quarters since.
48 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.